Alkermes (ALKS) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Alkermes (ALKS) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | -86.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.25% |
| Mar 31, 2026 | -22.13% |
| Dec 31, 2025 | -17.42% |
| Dec 31, 2024 | -79.25% |
| Sep 30, 2024 | 74.49% |
| Jun 30, 2024 | -54.04% |
| Mar 31, 2024 | 51.76% |
| Dec 31, 2023 | 1.41% |
| Sep 30, 2023 | -596.86% |
| Jun 30, 2023 | -12.65% |
| Mar 31, 2023 | 1.87% |
| Dec 31, 2022 | 66.97% |
| Sep 30, 2022 | -6.56% |
| Jun 30, 2022 | 10.47% |
| Mar 31, 2022 | 28.05% |
| Dec 31, 2021 | 89.27% |
| Sep 30, 2021 | 5.59% |
| Jun 30, 2021 | 27.49% |
| Mar 31, 2021 | 28.95% |
| Dec 31, 2020 | -63.32% |